Merck Builds Case for Cholesterol-Lowering Pill With Injectable-Like Efficacy

Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower low-density lipoprotein cholesterol by more than 55% after 24 weeks.